Clinical value of atorvastatin therapy in the treatment of contrast agent nephropathy after interventional therapy
10.3760/cma.j.issn.1008-6706.2018.21.022
- VernacularTitle:强化阿托伐他汀治疗经皮冠状动脉介入术后对比剂肾病的临床价值
- Author:
Chunying YU
1
;
Huantai WANG
Author Information
1. 烟台市莱阳中心医院心血管内科
- Keywords:
Nephrosis;
Coronary artery disease;
Radiology,interventional;
Contrast media;
Intensive Therapy;
Atorvastatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(21):2808-2810
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the protective effect of atorvastatin on patients with contrastor nephropathy after percutaneous coronary intervention (PCI).Methods From July 2016 to July 2017,94 patients with nephropathy in Laiyang Cenitral Hospital were enrolled in this study.The patients were randomly divided into twogroups,with 47 cases in each group.The observation group received atorvastatin intensive treatment,and the control group was treated with blank capsule.The changes of renal function before and after intervention,and the recovery time of clinical symptoms after intervention were compared.Results After intervention,the blood urea nitrogen and serum creatinine levels of the observation group were (6.1 ± 0.3) mmol/L and (81.5 ± 5.5) μmol/L,respectively,which were significantly lower those than before intervention [(26.5 ± 2.9) mmol/L,(491.5 ± 25.6) μmol/L] (t =47.970,104.730,all P ＜ 0.05) and those of the control group after intervention [(13.9 ± 2.0) mmol/L,(265.7 ± 31.8) μmol/L] (t =26.441,39.130,all P ＜ 0.05).After intervention,the recovery time of proteinuria,hypoalbuminemia,and edema disappeared time,normal blood lipid recovery time in the observation group were (11.3 ± 1.1) d,(21.3 ± 2.1) d,(4.1 ± 0.3) d and (45.3 ± 3.6) d,respectively,which were significantly shorter than those in the control group [(13.5 ± 1.3) d,(23.8 ± 2.6) d,(5.6 ± 0.4) d,(62.3 ± 4.2) d] (t =9.803,5.979,21.503,17.481,all P ＜ 0.05).Conclusion For the contrast agent nephropathy,the use of atorvastatin intensive therapy can effectively protect the patients' renal function,improve the clinical symptoms,which is worthy of clinical promotion.
